Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Palo Alto Networks Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Palo Alto Networks Inc trades at $356.6 (market cap $287.61B). The key difference: Palo Alto Networks Inc is far larger — about 35.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | PANW | |
|---|---|---|
Market Cap | $8.04B | $287.61B |
Sector | Health | Technology |
52-Week High | $339.75 | $357.53 |
52-Week Low | $241.71 | $141.67 |
Enterprise Value | $7.85B | $286.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Palo Alto Networks (PANW) trades at $330.30, up 1.35% with a bullish technical outlook and strong earnings beats. The stock shows robust revenue growth to $9.22B in 2025 and a net income margin of 7.95%, though valuation ratios like P/E of 287.22 remain elevated. Recent news highlights cybersecurity sector tailwinds from AI-driven threats and IBM's client shifts, fueling positive sentiment.
Outlook is positive with 74% analyst buy ratings and a $336.65 consensus target, but high valuations and integration costs pose risks. Revenue growth and platformization strategy support upside, while competition and macroeconomic pressures require monitoring for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
